Free Newsletter
Researchers narrow hunt for cure to stuttering
Researchers have been pursuing new leads in the search for a cure for stuttering. Scientists have found, for example, that stutterers often have an excess of dopamine, neurotransmitters, in the brain. And the fact that roughly half of stutterers who seek out treatment have a family member who also stutters raises the likelihood that there are genetic causes to the condition. Making the hunt for the right genetic trigger difficult is the notion that a number of genes may contribute to stuttering. Different teams have been narrowing the hunt to the genes in chromosome 1 and chromosome 12. Meanwhile, Indevus Pharmaceuticals has been successful so far in advancing a new therapy for stuttering. Last spring its researchers successfully wrapped the largest trial on stuttering to date, but still have two to three years of research work on pagoclone.
- here's the article from The New York Times on stuttering
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




